The ISTH has published new guidelines for antithrombotic treatment in COVID-19 in the Journal of Thrombosis and Haemostasis (JTH). The guidelines offer 12 recommendations, based on high or moderate-quality evidence available through March 2022, which are inclusive for all countries.

"For non-critically ill, hospitalized patients, there is a strong recommendation for use a of prophylactic dose low-molecular-weight heparin or unfractionated heparin (LMWH/UFH), whereas for select patients in this group, a therapeutic dose of LMWH/UFH is recommended rather than prophylactic dose, but a strong recommendation against the addition of an antiplatelet agent,” said Sam Schulman, M.D., Ph.D., chair of the guideline panel. “Weaker recommendations are given for or against antithrombotic for non-hospitalized, for hospitalized critically ill and for patients discharged from the hospital. The guidelines are accompanied by a Good Practice Statement document with additional suggestions in areas where only low-quality evidence is available.”

Click here to access the guidelines for antithrombotic treatment in COVID-19